Navigation Links
Innovive Pharmaceuticals Announces Data from Oncology Drug Programs,to be Presented at American Association for Cancer Research Annual,Meeting

NEW YORK--(BUSINESS WIRE)--Apr 10, 2007 - INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today announced that interim data from a Phase I trial of INNO-406, an orally bioavailable dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec-resistant or treatment-intolerant chronic myelogenous leukemia, will be presented at the American Association for Cancer Research Annual Meeting. Additionally, preclinical data on INNO-206, a doxorubicin prodrug for the treatment of various cancers, will be presented. The meeting takes place April 14-18, 2007 at the Los Angeles Convention Center in Los Angeles, California.

Information related to these presentations is as follows: -0-

Presentation Title:     "A phase I study of INNO-406, a dual inhibitor

                         of Abl/Lyn kinases, in adult patients with

                         imatinib-resistant or intolerant Philadelphia

                         chromosome positive (Ph+) leukemias"

----------------------- ----------------------------------------------

Abstract Number:        2637

----------------------- ----------------------------------------------

Session:                Poster Section 5, Clinical Research 11, Poster

                         Board #2

----------------------- ----------------------------------------------

Session Date and Time:  Monday, April 16, 2007, 1:00 p.m. - 5:00 p.m.

----------------------- ----------------------------------------------

Location:               Exhibit Hall, Los Angeles Convention Center

----------------------- ----------------------------------------------


----------------------- ----------------------------------------------

Presentation Title:     "Reduced chronic cardiotoxicity and

                         mitochondrial damage of the (6-

                         maleimidocaproyl) hydrazone derivative of

                         doxorubicin (DOXO-EMCH) in a rat model

                         compared to doxorubicin"

----------------------- ---------
'"/>




Page: 1 2 3

Related medicine technology :

1. Innovive Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting
2. Innovive Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program
3. Innovive Pharmaceuticals Announces Additional Data Presentations at American Association for Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:7/28/2014)... N.J. , July 28, 2014   ... $520,000 settlement of off-label marketing and fraud claims ... and Vascular Solutions, Inc. ("VSI").  The settlement covers ... medical devices for endovenous laser ablation of varicose ... Magnanini, a firm with a history of representing ...
(Date:7/28/2014)... -- June 28 th , 2014 – Oncolab, the ... cancer test, is making its AACC debut (booth #4051) at ... is a serum-based in vitro immunoassay, has been run for ... in the fight against cancer recurrence. Photo - ... million cancer survivors in the US alone, the race is ...
(Date:7/28/2014)... 2014 Reportlinker.com announces that a new ... Portugal Pharmaceuticals and Healthcare Report ... Includes 3 FREE quarterly ... growth last quarter has led us to revise ... forecast previously, BMI expects Portugal,s ...
Breaking Medicine Technology:Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 2Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 3Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4
... Prostate Conditions Education Council (PCEC) – a ... in prostate cancer screening – today announced it strongly ... Services Task Force (USPSTF). The draft guidance recommends against ... PCEC believes that until a more accurate and ...
... 10, 2011 PDI, Inc. (Nasdaq: ... R. Melillo, Jr. as senior vice president of Business ... drive PDI,s commercial outsource services and contract sales business. ... officer. Melillo was most recently general manager ...
Cached Medicine Technology:Prostate Conditions Education Council Opposes U.S. Preventative Services Task Force Recommendation 2Prostate Conditions Education Council Opposes U.S. Preventative Services Task Force Recommendation 3PDI Appoints Gerald R. Melillo, Jr. As SVP of Business Development 2
(Date:7/28/2014)... that they monopolize large amounts of sugar. More recently, ... characterized by a series of features such as mobility ... are calling this behavior "mesenchymal," and they suspect it ... was able to demonstrate that the two observations ... the same mechanism, at least in "non-small cell lung ...
(Date:7/28/2014)... 29, 2014 The “Tissue ... Hybridization, Digital pathology & Workflow, Special Staining), ... Cancer, Non Small Cell Lung Cancer and ... Pharmaceutical companies, Research Laboratories, Contract Research Organizations ... Europe, BRIC, Japan & RoW) - Trends ...
(Date:7/28/2014)... TX (PRWEB) July 28, 2014 A lush ... family playtime during the summer. However, the summer heat, lack ... lawn to become brown, weak and unhealthy. The Grounds Guys ... It Grow, Mow a lawn once a week and set ... than normal. This protects the grass roots from heat and ...
(Date:7/28/2014)... UHY LLP, a member of the ... UHY International Business – Issue 29. This bi-annual publication ... most current business challenges and key issues faced by ... the following topics:, , Key industry ... over the next five years? Where are growth opportunities ...
(Date:7/28/2014)... 2014 Dawn Echols’ professional background ... and music. This experience has honed her people ... psychology. Her professional counseling ( http://dawningphoenix.com ) work ... for offenders in domestic violence. , As ... she enjoys counseling individuals and groups for a ...
Breaking Medicine News(10 mins):Health News:Cancer: Tumors absorb sugar for mobility 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2
... Perot Systems,Corporation (NYSE: PER ) ... received the #1 ranking in the KLAS ... implementation services(1). Known throughout,the Healthcare industry for ... informed technology decisions by independently,monitoring vendor performance ...
... LA JOLLA, CA Diabetic individuals have a ... the molecular connection between the two remains unexplained. ... Studies identified the probable molecular basis for the ... published in the current online issue of Neurobiology ...
... How Drugs Actually Work in Real ... ... free,patient-driven online healthcare community, announced the launch of an,innovative new tool that ... taking prescription drugs, and eight out of,ten surfing the web for their ...
... Hillenbrand, Inc.,(NYSE: HI ) today announced that ... a publicly traded company of $0.1825 per share,on the ... 2008 to,shareholders of record at the close of business ... board to approve this inaugural dividend is based,on the ...
... Pet Week, May,4-10, celebrates the relationships formed between ... emphasize the caretaking actions we can take for ... recommended by,your veterinarian; giving them plenty of attention, ... pets safe and pleasant., "Being a responsible ...
... Tex. April 30, 2008 - Despite the general ... critically ill heart failure patients, implantation of these devices ... high-volume blood transfusions during and immediately after surgery. A ... that the incidence of these complications may be significantly ...
Cached Medicine News:Health News:Perot Systems Ranked #1 for Clinical Implementation Services By KLAS 2Health News:Perot Systems Ranked #1 for Clinical Implementation Services By KLAS 3Health News:Salk study links diabetes and Alzheimer's disease 2Health News:Salk study links diabetes and Alzheimer's disease 3Health News:iGuard.org Alters the Face of E-Health: New Web Service Draws 10,000 New Patients Weekly 2Health News:iGuard.org Alters the Face of E-Health: New Web Service Draws 10,000 New Patients Weekly 3Health News:Hillenbrand, Inc. Declares First Quarterly Dividend As a New Publicly Traded Company 2Health News:California Veterinarians Recognize National Pet Week With Tips to Keep Your Animal in a Safe Environment 2Health News:California Veterinarians Recognize National Pet Week With Tips to Keep Your Animal in a Safe Environment 3
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... nm and 940 nm) laser system is ... solid-state laser quickly and effectively treats vascular ... offers the clinical versatility to precisely target ... vessels in a convenient, affordable package. , ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
Medicine Products: